Summit Therapeutics Inc. (SMMT)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 22/100 (LOW), 36.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 30.56% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Upcoming Catalysts
- Ivonescimab — SMMT PDUFA 2026-11-14
Recent News & SEC Filings
- Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping Now
- AstraZeneca CEO Pascal Soriot on Summit ivonescimab combos
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
- Sector Update: Healthcare Stocks Steady Late Afternoon
- AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
- Summit Teams Up With Daiichi Sankyo, AstraZeneca For Cancer Therapy Trial – CEO Calls It An ‘Important Expansion’
- Summit Therapeutics (SMMT), What Is Behind The Fresh Attention?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Summit Therapeutics Inc..
Full SMMT Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.